Tag archive

Sygnature Discovery

Sygnature Discovery Boosts DMPK Capabilities with Four Senior Appointments

in Pharmaceutical News
Sygnature Discovery Boosts DMPK Capabilities with Four Senior Appointments

Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, has recruited four key individuals to boost its DMPK (drug metabolism and pharmacokinetics) capabilities. Dr Stuart Best, Dr Hayley Butler, Dr Daniel Weston and Dr Bodo Spöri have all joined the senior management team of the company’s DMPK department. Dr Stuart Best joins as Associate Director of DMPK and will manage and supervise the growth of the Alderley Park-based part of the DMPK team, which opened in 2018.…

Keep Reading

Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies

in Pharmaceutical News
Pathios Therapeutics and Sygnature Discovery sign a strategic and innovative partnership to develop first in class therapies in autoimmune disease and immuno-oncology

Pathios Therapeutics (“Pathios”), an innovative biotech company focused on the development of first in class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery (“Sygnature”), jointly announce a strategic partnership to accelerate Pathios’ drug discovery and development programmes. As part of the agreement, Pathios and Sygnature will collaborate on an integrated drug discovery programme against a novel G Protein-Coupled Receptor (GPCR) target. Specifically, Sygnature are providing their industry leading expertise in GPCR bioscience and medicinal chemistry to expand Pathios’ current…

Keep Reading

Go to Top